Related Experiment Video
Updated: Apr 5, 2026
03:20
Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
Published on: September 22, 2023
2.5K
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Linda M Henricks1,2, Carin A T C Lunenburg3, Didier Meulendijks1,2
1Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pharmacogenomics
|August 13, 2015
Summary
Dihydropyrimidine dehydrogenase (DPD) deficiency, caused by DPYD gene variants, leads to severe toxicity from fluoropyrimidine drugs. A new gene activity score helps personalize drug doses for better safety and effectiveness.
Area of Science:
- Pharmacogenomics
- Biochemistry
- Clinical Pharmacology
Background:
- Dihydropyrimidine dehydrogenase (DPD) is crucial for metabolizing fluoropyrimidine drugs.
- DPD deficiency, affecting 4-5% of patients, causes severe drug toxicity.
- Specific DPYD gene single nucleotide polymorphisms (SNPs) result in reduced or absent DPD activity.
Purpose of the Study:
- To develop a standardized method for adjusting fluoropyrimidine drug doses based on DPYD genotype.
- To translate DPYD genetic variations into a functional DPD enzyme activity score.
- To improve the safety and efficacy of fluoropyrimidine chemotherapy.
Main Methods:
- Analysis of various DPYD gene SNPs associated with DPD deficiency.
- Development of a gene activity score integrating the functional impact of different SNPs.
- Correlation of the gene activity score with predicted DPD enzyme activity.
Main Results:
- Identified key DPYD SNPs (DPYD*2A, DPYD*13, c.2846A>T, c.1236G>A/haplotype B3) impacting DPD activity.
- Proposed a gene activity score to quantify the combined effect of these SNPs.
- Demonstrated the score's potential for differentiating dose adjustments.
Conclusions:
- The gene activity score offers a standardized approach to individualized fluoropyrimidine dosing.
- This pharmacogenomic tool can optimize treatment by accounting for DPYD genotype-phenotype correlations.
- Implementing the gene activity score can enhance patient safety and therapeutic outcomes in fluoropyrimidine chemotherapy.
